MOH

Molina Healthcare is projected to report a 60.9% earnings decline in Q3 2026 with revenues falling 4.8%. The company faces multiple headwinds including a 12.7% membership decline (63% drop in Marketplace enrollment), rising medical care ratio to 93%, and falling premium revenues and investment income. The stock has a negative Earnings ESP of -3.30% and Zacks Rank #4 (Sell), making an earnings beat unlikely.

Oscar Health (OSCR) is positioned as the stronger investment compared to Molina Healthcare (MOH), driven by robust 46% membership growth, 70% revenue increase, a 20% revenue CAGR target through 2027, and a lower valuation multiple. Molina faces headwinds from rising medical costs, enrollment challenges, and portfolio restructuring, with a projected 2027 exit from its MAPD business and $1 billion marketplace premium reduction.

Molina Healthcare is expected to report a significant year-over-year earnings decline of 60.9% to $0.72 per share for Q3 2026, with revenues down 4.8% to $10.93 billion. The stock carries a Zacks Rank #4 (Sell) with a negative Earnings ESP of -3.30%, making it unlikely to beat consensus estimates. While the company has beaten estimates in 2 of the last 4 quarters, current analyst sentiment has turned bearish with recent estimate revisions.